PRVA Q1 revenue +25.8% on Evolent ACO, but net income -27.4% as tax provision surges

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read

Key Changes

• high

  Operating income rose 42.2% YoY to $7.4M, but net income fell 27.4% to $3.1M as income tax provision surged 166% (from $2.1M to $5.6M) on share-based compensation impacts and noncontrolling interest income dropped 64.6% following NCI repurchases—a $3.4M net below-the-line drag that reversed the operating gain.

  MD&A: Net Income verify on EDGAR →
• high

  Acquired Evolent Health ACO in Dec 2025, adding 120k+ attributed lives across MSSP, commercial, and Medicare Advantage; total ACO count now ten, up from nine at start of 2025.

  MD&A: ACO Acquisition verify on EDGAR →
• high

  Shared savings revenue jumped 56.5% YoY to $75.0M (vs. 0.9% growth prior year) on timing of accruals/settlements and strong VBC performance; Attributed Lives +26.5% to 1.6M.

  MD&A: Shared Savings verify on EDGAR →